This narrative review addresses the multi-layered nature of osteoclast-osteoblast communication and the molecular logic governing coupling, which the authors note remains incompletely understood. The scope of the discussion centers on the potential of pre-osteoclasts to function as major, and potentially dominant, coupling effectors within the skeletal system. The authors suggest that therapeutic strategies aimed at expanding the coupling-competent pre-osteoclast pool could represent a paradigm shift toward next-generation skeletal therapies.
The review highlights that the relative contribution of pre-osteoclast-derived signals versus other coupling mechanisms varies by skeletal site, age, and pathological context. Consequently, the authors caution against overinterpreting the mechanistic separation of anabolic and resorptive functions of the osteoclast lineage as a definitive clinical reality. These nuances underscore the complexity of the biological processes involved in bone remodeling and regeneration.
While the authors propose exciting future directions, the review does not report specific study populations, sample sizes, or adverse events, as it synthesizes existing knowledge rather than presenting primary trial data. The practice relevance is framed cautiously, suggesting that current understanding is incomplete and that further research is needed to validate these mechanistic insights before they can be fully integrated into clinical practice.
View Original Abstract ↓
Skeletal homeostasis depends on tightly coordinated communication between osteoclasts and osteoblasts, yet the molecular logic governing this coupling remains incompletely understood. This review reframes the osteoclast–osteoblast relationship by integrating developmental biology, molecular signaling, and translational perspectives into a unified analytical framework. We first trace the developmental origins of osteoclasts across embryonic hematopoietic waves, presenting evidence that ontogenetic heterogeneity—rather than being a developmental relic—actively shapes the coupling capacity of osteoclast populations throughout life. We then examine the hierarchical differentiation cascade of the osteoblast lineage, emphasizing how the adipo-osteo switch and hormonal regulation at each differentiation stage create multiple points of vulnerability and therapeutic opportunity. A central argument of this review is that pre-osteoclasts function as major, and potentially dominant, coupling effectors in bone remodeling. Operating through a secretome that includes sphingosine-1-phosphate, PDGF-BB, and afamin, these mononuclear precursors coordinate osteoblast recruitment and vascularization independently of bone resorption. However, the relative contribution of pre-osteoclast-derived signals versus other coupling mechanisms likely varies by skeletal site, age, and pathological context. We systematically dissect three core signaling cascades—BMP, sphingolipid/sclerostin, and WNT—and argue that their functional convergence creates a robust yet tunable communication network. We further evaluate recently identified coupling factors including cardiotrophin-1, SLIT3, C3a, and CTHRC1, alongside surface-mediated and vesicle-based communication systems. Finally, we critically assess current therapeutic strategies through the lens of coupling biology, proposing that the persistent failure to develop truly disease-modifying skeletal therapies stems from an incomplete appreciation of the multi-layered nature of osteoclast–osteoblast communication. Collectively, this review establishes that the anabolic and resorptive functions of the osteoclast lineage are mechanistically separable and proposes that therapeutic strategies aimed at expanding the coupling-competent pre-osteoclast pool—rather than broadly suppressing or stimulating remodeling—represent a paradigm shift toward next-generation skeletal therapies that preserve, rather than disrupt, the endogenous coupling network.